Results 181 to 190 of about 15,814 (215)

Undifferentiated Purpuric and Desquamative Drug Eruption After Pembrolizumab and Empagliflozin Exposure: A Clinicopathologic Diagnostic Pitfall. [PDF]

Cureus
Biswas N, Khokhar I, Fu JJ.
europepmc   +1 more source

Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function. [PDF]

Diabetes Obes Metab
Nobayashi H, Satoh M, Hirose T, Nakayama S, Iwabe Y, Hashimoto H, Murakami T, Okada K, Mori T, Metoki H.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Empagliflozin

Reactions Weekly
  +18 more sources

Empagliflozin

Reactions Weekly, 2023
  +12 more sources

Empagliflozin in the elderly

Gériatrie et Psychologie Neuropsychiatrie du Viellissement, 2021
Glucose and sodium tubular reabsorption inhibitors, or gliflozins, are a new therapeutic class. Their novel mechanism of action involves inhibition of a glucose and Na+ reabsorption co-transporter in the renal proximal tubule. They reduce blood glucose levels by reducing renal glucose reabsorption.
Gilles, Berrut, Anne Sophie, Boureau, Jean Noel, Trochu, Bastien, Genet, Laure, de Decker, Olivier, Hanon   +5 more
openaire   +3 more sources

Assay of Empagliflozin in Empagliflozin Tablets by HPLC

International Journal of Drug Delivery Technology
Background: Empagliflozin is a member of the sodium-glucose co-transporter 2 (SGLT2) inhibitor class, which helps lower blood glucose levels by promoting the excretion of glucose through urine. It is indicated for type 2 diabetes and is not suitable for managing type 1 diabetes, where insulin production is absent.
Dr. Parag Das, Mr. Updesh Singh, Mr. Animesh Maity, Mr. Amrit Kumar Rath, Prof. (Dr.) Sruti Ranjan Mishra, Mrs. Amrita Nayak, Mrs. Manashi Das   +6 more
openaire   +1 more source

Empagliflozin

Reactions Weekly, 2021
  +5 more sources

Empagliflozin

Reactions Weekly, 2020
  +5 more sources